Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes

European Journal of Preventive Cardiology

Volumn 13, Issue 2, 2006, Pages 193-198

  Gerber, Yariv ^a   Tanne, David ^a,b   Medalie, Jack H ^c   Goldbourt, Uri ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COURSE EVALUATION; FOLLOW UP; HAZARD ASSESSMENT; HEART DEATH; HEART RATE; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; STROKE; URIC ACID BLOOD LEVEL; WORKER;

BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CORONARY DISEASE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TIME FACTORS; URIC ACID;

EID: 33746228618     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000192745.26973.00     Document Type: Article

References (37)

1. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369–379.
2. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126–130.
3. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–1431.
4. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072–1078.
5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404–2410.
6. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11–18.
7. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401–410.
8. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003; 41: 1183–1190.
9. Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death?. Lancet 1999; 354: 1578.
10. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
11. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147–153.
12. Yusuf S, Bosch J. Urate levels as a predictor of cardiac deaths: causal relation or mere association? Eur Heart J 2002; 23: 760–761.
13. Waring WS, Webb DJ, Maxwell SR. Uric acid as a risk factor for cardiovascular disease. Q J Med 2000; 93: 707–713.
14. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635–639.
15. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol 2001; 17: 1097–1104.
16. Wong KY, MacWalter RS, Fraser HW, Crombie I, Ogston SA, Struthers AD. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002; 23: 788–793.
17. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951–1956.
18. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002; 33: 1048–1052.
19. Sridharan R. Risk factors for ischemic stroke: a case control analysis. Neuroepidemiology 1992; 11: 24–30.
20. Groen JJ, Medalie JH, Neufeld HN, Riss E, Bachrach CA, Mount FW, et al. An epidemiologic investigation of hypertension and ischemic heart disease within a defined segment of the adult male population of Israel. Isr J Med Sci 1968; 4: 177–194.
21. Medalie JH, Kahn HA, Neufeld HN, Riss E, Goldbourt U, Perlstein T, et al. Myocardial infarction over a five-year period. I. Prevalence, incidence and mortality experience. J Chronic Dis 1973; 26: 63–84.
22. Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 1982; 2: 240–243.
23. Anderson JT, Keys A. Cholesterol in serum and lipoprotein fractions; its measurement and stability. Clin Chem 1956; 2: 145–159.
24. Tanne D, Yaari S, Goldbourt U. Risk profile and prediction of long-term ischemic stroke mortality: a 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation 1998; 98: 1365–1371.
25. Kahn HA, Herman JB, Medalie JH, Neufeld HN, Riss E, Goldbourt U. Factors related to diabetes incidence: a multivariate analysis of two years observation on 10,000 men. The Israel Ischemic Heart Disease Study. J Chronic Dis 1971; 23: 617–629.
26. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.
27. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017–1027.
28. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33.
29. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995; 268: E1–E5.
30. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008–3011.
31. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403–409.
32. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546–1551.
33. Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 2004; 11: 185–191.
34. Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27: 484–490.
35. Skinner KA, White CR, Patel R, Tan S, Barnes S, Kirk M, et al. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 1998; 273: 24491–24497.
36. Gerber Y, Dankner R, Chetrit A, Novikov I, Goldbourt U. The role of risk factor time trends in the steep decline of CHD mortality between two Israeli cohort studies. Prev Med 2005; 41: 85–91.
37. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–1049.